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Cancer is a foremost health problem worldwide 
and is the leading source of human mortality 
exceeded only by cardiovascular diseases [1-
3]. This fact makes the innovation of new 
anticancer drugs and more effective treatment 
strategies for cancer of utmost importance 
Chemistry & Biology Interface, 2019, 9, 3, 148-156
Synthesis and biological evaluation of 2,4-diaminopyrimidine-5-carbonitrile and 
N-(2-amino-5-cyanopyrimidin-4-yl)benzamide derivatives as EGFR inhibitors
Pathan Sultan Ismaila, Irfan Khanb, Vivek Kumarc,  Ved Prakash Vermad, Monika Shuklad,  An-
upam Dhasmanae, Shashi Pandeyf, Girdhar Pal Singha *  Shahnawaz Khan g* and  Jaybir Singhh*
aDepartment of Chemistry, Bhupal Nobles’University-313001 Udaipur, India.
bCo-Ordination Chemistry Laboratory, Department of Chemistry, Mohan Lal Sukhadia University, Udaipur (Rajas-
than) India.
cHuman Genome and Stem-cell Center (HUG-CELL), Department of Genetics & Evolutionary Biology, Institute of 
Biosciences, University of São Paulo, Butanta, 05,508,090 -São Paulo, SP – Brazil
dDepartment of Chemistry, Banasthali Vidyapith Newai – 304022
eHimalayan School of Bio sciences, Swami Rama Himalayan University, Dehradun, India 
fDepartment of Chemistry, R.D. College, Sheikhpura (Munger University, Munger) Bihar, 811105
gDepartment of Chemistry, J.R.N. Rajasthan Vidyapeeth (Deemed to be University), Udaipur (Raj.), India.
hDepartment of pharmacy, Dr. B. R. Ambedkar University, Agra (India) 282002 
Email - * jbmpharm@gmail.com  * khancdri@gmail.com
Received 8 May 2019; Accepted 29 June 2019
Abstract: A series of 2,4-diaminopyrimidine-5-carbonitrile and N-(2-amino-5-cyanopyrimidin-4-yl) ben-
zamide derivatives (5–14) were synthesized and their chemical structures were confirmed by 1 H, 13C 
NMR and mass spectral data. Anticancer activity of all the synthesized compounds were evaluated for in 
vitro cytotoxic activity against a panel of four human cancer cell lines i.e., human breast (MCF-7,), cervical 
cancer (C33A), oral (KB) and prostrate (DU-145). All the examined compounds, demonstrated potent to 
moderate anticancer activity. Among all the synthesized compounds, 6 and 11 were exhibited more potent 
activity. Docking studies for 6 and 11 into EGFR active site was carried out to investigate their potential 
binding modes. Therefore, compounds 6 and 11 can be considered as fascinating candidates for further 
expansion of more potent anticancer agents.
Keywords: Anticancer, EGFR inhibitors, Molecular docking, 2,4-diaminopyrimidine-5-carbonitrile and 
N-(2-amino-5-cyanopyrimidin-4-yl) benzamide. 
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as traditionally prescribed chemotherapeutic 
agents have problems with toxicity and drug 
resistance. We are at an important crossroad in 
cancer research and clinical oncology where we 
should believe courageous new strategies for 
cancer treatment [4-5]. Immense progress have 
been made mapping out the cellular pathways 
altered in tumors and the pathways that counter 
to cancer treatment. The obvious significance 
of the components of DNA damage response 
pathways as potential cancer therapeutic targets 
has stimulated researchers and pharmaceutical 
companies to build up numerous chemical 
inhibitors for many of the proteins involved 
in these pathways [6-7]. Even though, various 
kinase inhibitors have been discovered in 
recent times and several have been successfully 
developed for treatment of cancer including 
Gleevec, Iressa, Tarceva, Tykerb, and Sutent, 
still there is strong required for breakthrough 
of improved cytotoxic agents[8-9].  As most of 
the solid human cancer tumor are multi causal 
in nature and their treatment with “mechanism-
based” agent alone is unlikely to be successful, 
so a combination of these inhibitors with a 
better cytotoxic drug is likely to be a good 
strategy. A receptor tyrosine kinase, epidermal 
growth factor receptor (EGFR), demonstrates 
a critical function regarding the regulation 
of several cellular roles such as cell survival, 
proliferation, differentiation and migration 
[9]. EGFR mediates intracellular signaling 
(intrinsic intracellular protein-tyrosine kinase 
activity) is reply to different extracellular 
stimuli (endogenous ligand, like epidermal 
growth factor (EGF) and transforming growth 
factor α (TGFα)), foremost to DNA synthesis 
and cell growth [10,11]. EGFR over expression 
caused by Mutations which and establishment 
are associated with wide variety of cancer types 
as breast cancer, colorectal carcinoma, non-
small cell lung cancer and pancreatic cancer 
[12]. Consequently, disruption of the signaling 
pathway of EGFR, either extracellular by 
blocking the binding site of EGFR inhibiting 
the tyrosine kinase activity, is significant in 
cancer prevention and treatment [13,14]. It has 
been recognized that EGFR is one of the most 
significant targets for improvement of novel 
cancer therapeutics [15–17].  Based on the 
above information, require and huge interest in 
the discovery of new chemical entities and novel 
lead structures. Quinazoline is one of the most 
vital heterocyclic scaffolds that become known 
as a potential privileged scaffold in cancer 
drug discovery [18–20]. Interestingly, there 
are numerous clinically accepted quinazoline-
based anticancer drugs with potent EGFR-
TK inhibitory activity such as Gefitinib [21], 
Afatinib [22], Erlotinib [23], Icotinib [24] and 
Lapatinib (Fig. 1) [25].
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Fig. 1 An amount of clinically approved 
EGFR-TK inhibitors based on quinazoline and 
quinoline scaffolds.
The synthesis of 2,4-diaminopyrimidine-5-
carbonitrile and N-(2-amino-5-cyanopyrimidin-
4-yl)benzamide that are known to inhibit 
EGFR-TK, phosphodiesterase and ATPase, 
AMPA, Gly/NMDA and Kainate receptor, 
xanthine oxidase and benzodiazepine receptor. 
Conventionally, 2,4-diaminopyrimidine-5-
carbonitrile are synthesized in a multi-step 
fashion. Design and assembly of compound 
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collections based on small molecules generated 
from multicomponent routes, play a decisive role 
in driving drug discovery research, since their 
protein targets exhibit connectivity distribution 
closer to human disease genes. Owing to their 
structural resemblance with known anticancer 
drug, erlotinib and gefitinib, biological 
investigation of 2,4-diaminopyrimidine-5-
carbonitrile on cancer cell lines of human 
breast (MCF-7,), cervical cancer (C33A), oral 
(KB) and prostrate (DU-145) was carried out. 
A corresponding focused compound collection 
produced mechanism based inhibitors of 
Epidermal Growth Factor Receptor (EGFR) 
cancer cell deaths.   
Experimental
All reagents and solvents were purchased 
from commercial sources and used without 
purification. NMR spectra were recorded 
with 200, 300, 400 MHz spectrometers for 1H 
NMR and 50, 75, 100 MHz for 13C NMR on 
Bruker Supercon Magnet Avance DRX-300 
spectrometers in deuterated solvents with TMS 
as internal reference (chemical shifts δ in ppm, 
coupling constant J in Hz.). Multiplicities are 
reported as follows: singlet (s), doublet (d), 
triplet (t), multiplet (m), and broad singlet (br 
s). Mass spectra and HRMS were taken in the 
ESI positive ion mode. Microwave reactions 
were conducted using a Biotage Initiator in 
10-mL glass tubes, sealed with Teflon septum 
and placed in the microwave cavity. The 
reaction progress was monitored by thin layer 
chromatography (TLC) on pre-coated silica gel 
plates. Column chromatography was performed 
over Merck silica gel (230-400 flash). All 
compounds were characterized by TLC, 1H 
NMR and 13C NMR, MS and HRMS. 
General Procedure for the synthesis of 
various 2,4-diaminopyrimidine-5-carbonitrile 
and N-(2-amino-5-cyanopyrimidin-4-yl)
benzamide derivatives 
The synthesis of Synthesis and biological 
evaluation of 2,4-diaminopyrimidine-5-
carbonitrile and N-(2-amino-5-cyanopyrimidin-
4-yl)benzamide derivatives as EGFR inhibitors 
involved following steps: 
S NH2
NH
.H2SO4
H
O
CN
CN+
N
N
CN
NH2S
N
N
CN
NH2S
O O
N
N
CN
NH2R
N
N
CN
NHR
O
1 2 3
4
5-910-14
I II
III
IV
DIPA/DMF
10°C-30°C
m-MCPBA/THF
Amine
THF
KOtBu
Benzoyl chloride
DMF
10°C-30°C
10°C-30°C
 
Reagent and condition: (I) diisopropylethyl 
amine, DMF, 10°C to 25-30°C.; (II) 3-chloro 
peroxybenzoic acid, THF, 10°C to 25-30°C.;; 
(III) amines, THF, reflux; (IV) benzoyl chloride, 
potassium tert. butoxide, DMF, 10°C to 25-
30°C 
Compound 4-amino-5-cyano-2-
methylthiopyrimidine (5-9) was synthesize by the 
reaction of S-methyl thiourea hydrogen sulphate 
and ethoxymethylene malonitrile (EMMN) in 
the presence of diisopropylethylamine in dry 
DMF at 0oC to r.t. Compound 3 was oxidized 
with m-chloroperoxybenzoic acid to obtain the 
sulphone (4), which on nucleophilic substitution 
with various amines furnished the compounds 
5-9. Compounds 5-9 were benzoylated 
separately with benzoyl chloride in the presence 
of potassium tert. butoxide in dry DMF at 0o 
C–r.t. to obtain compounds 10–14.
Characterization data of compounds:
Compound 5: 4-amino-2-
morpholinopyrimidine-5-carbonitrile 
Solid, Yield 73%, 1H NMR (400 MHz, CDCl3): 
δ 12.43 (s, 1H), 8.78 (s, 1H), 5.98 (s, 2H), 4.56 
– 4.36 (m, 4H), 4.34 – 4.23 (m, 4H)., 13C NMR 
(101 MHz, CDCl3) δ 162.96, 161.26, 160.97, 
133.37, 128.99, 116.94, 79.48, 66.71, 45.87, 
44.13 ppm, HRMS (ESI) Calcd. for C9H11N5O 
[M+H]+ 206.1036 Found 206.1001. 
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Table 1. Synthesis of substituted 4-amino-5-cyano-2-methylthiopyrimidine system
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Table 2. Synthesis of substituted N-(2-amino-5-cyanopyrimidin-4-yl)benzamide derivatives 
system 
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Compound 6: 4-amino-2-(4-(2-
methoxyphenyl)piperazin-1-yl)pyrimidine-
5-carbonitrile
Solid, Yield 67%, 1H NMR (400 MHz, CDCl3): 
δ 8.61 (s, 1H), 7.46 – 7.37 (m, 1H), 7.35 – 7.23 
(m, 3H), 5.67 (s, 2H), 4.48 – 4.34 (m, 4H), 4.27 
(s, 3H), 3.76 – 3.27 (m, 4H). ppm, 13C NMR 
(101 MHz, CDCl3) δ 163.09, 161.43, 160.99, 
152.35, 123.62, 121.12, 118.51, 117.18, 111.32, 
79.21, 77.48, 55.55, 50.73, 44.03,, HRMS (ESI) 
Calcd. for C16H18N6O [M+H]
+
 311.1615 Found 
311.1611
Compound 7: 4-amino-2-(piperidin-1-yl)
pyrimidine-5-carbonitrile 
Solid, Yield 57%, 1H NMR (400 MHz, CDCl3): 
δ 8.82 (s, 1H), 5.91 (s, 2H), 4.55 – 4.24 (m, 4H), 
2.36 – 2.24 (m, 2H), 2.24 – 2.12 (m, 4H), 2.07 
– 1.97 (m, 2H)., 13C NMR (101 MHz, CDCl3) 
δ 163.02, 161.26, 160.65, 133.46, 130.14, 
128.51, 117.38, 78.48, 77.16, 45.94, 45.02, 
25.90, 24.75., HRMS (ESI) Calcd. for C10H13N5 
[M+H]+ 204.1244 Found 204.1243
Compound 8: 4-amino-2-(4-benzylpiperazin-
1-yl)pyrimidine-5-carbonitrile 
Solid, Yield 49%, 1H NMR (400 MHz, CDCl3) 
δ 8.82 (s, 1H), 7.99 – 7.93 (m, 4H), 7.92 – 7.88 
(m, 1H), 5.86 (s, 2H), 4.57 – 4.39 (m, 4H), 
4.16 (s, 2H), 3.17 – 3.01 (m, 4H), 13C NMR 
(101 MHz, CDCl3) δ 163.05, 161.39, 160.93, 
137.74, 129.32, 128.45, 127.39, 117.21, 79.08, 
76.84, 63.11, 52.91, 43.79,, HRMS (ESI) Calcd. 
for C16H18N6 [M+H]
+
 295.1666 Found 295.1659. 
Compound 9: 4-amino-2-(4-methylpiperazin-
1-yl)pyrimidine-5-carbonitrile 
Solid, Yield 54%, 1H NMR (400 MHz, CDCl3): 
δ 8.19 (s, 1H), 5.32 (s, 2H), 4.26 – 3.14 (m, 4H), 
2.56 – 2.36 (m, 4H), 2.30 (s, 3H).ppm, 13C NMR 
(101 MHz, CDCl3) δ 163.07, 161.38, 160.97, 
117.16, 79.18, 54.85, 46.20, 43.68., HRMS 
(ESI) Calcd. for C10H14N6 [M+H]
+
 219.1353 
Found 219.1353. 
.
Compound 10: N-(5-cyano-2-
morpholinopyrimidin-4-yl)benzamide 
Solid, Yield 54%, 1H NMR (400 MHz, CDCl3): 
8.78 (s, 1H), 8.42-8.33 (m, 2H), 8.20-8.07 
(m, 3H), 6.27 (br s, 1H) 4.63 – 4.42 (m, 4H), 
4.42 – 4.37 (m, 4H)., 13C NMR  (101 MHz, 
CDCl3) δ 168.3 162.96, 161.26, 160.97, 134.6, 
133.37, 132.4, 128.99, 128.6, 126.9, 116.94, 
79.48, 66.71, 45.87, 44.13 ppm, HRMS (ESI) 
Calcd. for C16H15N5O2 [M+H]
+
 310.1299  Found 
309.1200
Compound 11: N-(5-cyano-2-(4-(2-
methoxyphenyl)piperazin-1-yl)pyrimidin-4-
yl)benzamide
Solid, Yield 67%, 1H NMR (400 MHz, CDCl3): 
δ 8.61 (s, 1H), 8.39-8.33 (m, 2H), 8.12-8.02 
(m, 3H), 7.46 – 7.37 (m, 1H), 7.35 – 7.23 (m, 
3H), 6.34 (br s, 1H), 4.48 – 4.34 (m, 4H), 4.27 
(s, 3H), 3.76 – 3.27 (m, 4H). ppm, 13C NMR 
(101 MHz, CDCl3) δ 169.2,164.9, 160.7, 159.2, 
151.35, 133.6, 131.9,127.9,126.4,123.40, 
120.12, 117.99, 116.18, 110.42, 79.66, 76.48, 
56.54, 50.90, 43.77,, HRMS (ESI) Calcd. for 
C23H22N6O2 [M+H]
+
 415.1877 Found 415.1789
Compound 12: N-(5-cyano-2-(piperidin-1-yl)
pyrimidin-4-yl)benzamide 
Solid, Yield 55%, 1H NMR (400 MHz, CDCl3): 
δ 8.88 (s, 1H), 8.65-8.50 (m, 2H), 8.20-8.09 (m, 
3H), 6.37 (br s, 1H), 4.65 – 4.57 (m, 4H), 2.77 
– 2.67 (m, 2H), 2.34 – 2.22 (m, 4H), 2.17 – 1.99 
(m, 2H)., 13C NMR (101 MHz, CDCl3) δ 168.7 
163.7, 161.66, 160.99, 134.6 133.46, 131.4, 
130.14, 128.7, 128.51, 126.9,117.88, 78.78, 
77.16, 46.54, 45.55, 26.30, 24.95., HRMS (ESI) 
Calcd. for C17H17N5O [M+H]
+
 308.1506 Found 
308.1504
Compound 13: N-(2-(4-benzylpiperazin-1-
yl)-5-cyanopyrimidin-4-yl)benzamide 
Solid, Yield 49%, 1H NMR (400 MHz, CDCl3) 
δ 9.01 (s, 1H), 8.67-8.53 (m, 2H), 8.33-8.21 (m, 
3H), 8.07-8.00 (m, 4H), 7.98 – 7.93 (m, 1H), 
6.69(br s, 1H), 4.63 – 4.42 (m, 4H), 4.23(s, 2H), 
Chemistry & Biology Interface, 2019, 9, 3, 148-156
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3.25 – 3.07 (m, 4H), 13C NMR (101 MHz, CDCl3) 
δ 169.2, 164.75, 162.59, 161.25, 138.21,135.2, 
134.9, 129.62, 128.9, 128.55, 127.72, 117.9, 
79.75, 76.82, 63.69, 53.98, 44.79,, HRMS (ESI) 
Calcd. for C23H22N6O [M+H]
+
 399.1928 Found 
399.1917.
Compound 14: N-(5-cyano-2-(4-
methylpiperazin-1-yl)pyrimidin-4-yl)
benzamide 
Solid, Yield 54%, 1H NMR (400 MHz, CDCl3): 
δ 8.24 (s, 1H), 8.11-8.03 (m, 2H), 8.01-7.91 (m, 
3H), 6.21(br s, 1H), 4.21 – 3414 (m, 4H), 2.67 
– 2.4 (m, 4H), 2.50 (s, 3H).ppm, 13C NMR (101 
MHz, CDCl3) δ 168.1, 163.07, 162.38, 161.94, 
134.0, 131.4, 128.5, 127.0, 117.55, 79.34, 
55.85, 47.80, 43.78., HRMS (ESI) Calcd. for 
C17H18N6O [M+H]
+
 323.1615 Found 323.1550  
Anticancer activity 
The anticancer activity of the synthesized 
compounds  was evaluated against four 
cancerous cell lines; human breast (MCF-7,), 
cervical cancer (C33A), oral (KB) and prostrate 
(DU-145) using (SRB) colorimetric assay. 
Doxorubicin and Erlotinib were included in the 
experiments as reference cytotoxic compounds 
for all the tested cell lines. The results were 
expressed as median growth inhibitory 
concentration (IC50) values, which represent the 
concentration of a drug that is required for 50% 
inhibition of cell growth after 48 h of incubation, 
compared to untreated controls (Table 2).
Table 2.  In vitro anticancer activity of 
compounds (5-14).
Compound
No.
IC50 (µg/mL)
DU 
145 MCF7 C33A KB VERO
5 15.8 23.4 21.7 15.6 24.3
6 3.0 1.4 1.6 2.8 37.8
7 20.2 28.0 24.9 21.6 33.7
8 8.9 4.3 3.3 3.9 8.2
9 10.1 5.2 4.2 4.5 9.8
10 2.5 3.2 3.1 6.0 2.6
11 0.2 1.6 4.2 1.5 5.9
12 4.5 3.9 2.5 5.1 7.8
13 21.3 35.2 26 33.4 29.7
14 23.0 32.4 19.8 22.8 37.8
All of the tested compounds showed potent to 
moderate activity with IC50 values ranging from 
0.21 to 35.2 μM. In particular, compounds 6 and 
11 were the most active compounds through 
this study with IC50 values equal 1.4and 0.2 μM, 
respectively. 
Molecular docking 
Docking of the most potent EGFR-TK inhibitors 
(6 and 11) was passed out to study their pattern 
of binding and potential binding interactions 
into the ATP binding site of the EGFR kinase 
domain. The ability of compounds 6 and 11 to 
interact with the key amino acids in the ATP 
binding site of EGFR-TK rationalized their 
promising antitumor activities. In silico study 
clearly depicted that compound 11 poses higher 
and strong binding ability with EGFR (PDB ID: 
1XKK) over compound 6. Compound 11 and 
EGFR bind with binding energy -8.25 Kcal/
Mol, dissociation constant (Ki) 898.49 nM and 
N20 atom of compound 11 formed hydrogen 
bond with Nitogen atom of GLY796 with 
distance of 3.03318 Ǻ, total 19 amino acids of 
EGFR are involved in hydrophobic interactions. 
On other hand side Compound 6 posses lesser 
binding energy than compound 11, it was 
-6.28 Kcal/Mol, 24.81 µM Ki and also form a 
hydrogen bond with H41 atom of compound 6 
with Oxygen atom of Leu788 residue of EGFR 
hydrogen bond distance is 2.24605 Ǻ, at last 
total 16 amino acids of EGFR are involved in 
hydrophobic interactions with compound 6 (as 
shown in table 3 and Figure 2).
Chemistry & Biology Interface, 2019, 9, 3, 148-156
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Figure 2: A) Binding pose of Compound 11 
and EGFR B) Binding pose of Compound 6 
and EGFR.
Material and Methods:
RCSB protein data bank was used to procure 3D 
structure of EGFR (PDB ID 1XKK: Chain A). 
1XKK was edited to remove HETATM using 
Discovery Studio Visualizer 3.1. Auto Dock 
Tool 4 (MGL Tool) was used for the molecular 
docking, identification of binding affinities and 
poses of ligands and proteins. (Morris GM et al 
2009 and Dhasmana A et al 2016).
Conclusions
In summary, a series of novel 
2,4-diaminopyrimidine-5-carbonitrile and 
N-(2-amino-5-cyanopyrimidin-4-yl)benzamide 
derivatives d was designed, synthesized and 
evaluated as potent EGFR inhibitors. The results 
showed that most of synthesized compounds 
exhibited moderate to high anticancer activities 
against four human tumor cell lines including 
human breast (MCF-7,), cervical cancer (C33A), 
oral (KB) and prostrate (DU-145) using (SRB) 
colorimetric assay and EGFR Kinase. 
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A:LEU788:O
2.24605
2 1XKK Compound 11 -8.25
898.49 
nM
Leu718,Val726,Ala743
Lys745,Met766,Leu777
Leu788,Ile789,Thr790
Leu792,Met793,Gly796
Cys797,Asp800,Leu844
Thr854,Asp855,Leu858
Met1002
A:GLY796:N 
- :Compound 
11:N20
3.03318
Table3: Binding pattern of Compound 6 and 11 with EGFR protein.
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